INVERSE CORRELATION BETWEEN KI67 EXPRESSION AND STEROID RECEPTORS IN PATIENTS WITH BREAST CARCINOMA

  • Ognjen Zivkovic Institut za onkologiju i radiologiju Srbije, Služba za patološku i drugu dijagnostiku, Beograd, Srbija
  • Andjela Milicevic Institut za onkologiju i radiologiju Srbije, Služba za patološku i drugu dijagnostiku, Beograd, Srbija
  • Ivana Petrovic Institut za onkologiju i radiologiju Srbije, Služba za patološku i drugu dijagnostiku, Beograd, Srbija
  • Jelena Rakocevic Institut za histologiju i embriologiju „Prof. dr Aleksandar Đ. Kostić“, Medicinski fakultet Univerziteta u Beogradu
  • Zorka Inic Institut za onkologiju i radiologiju Srbije, klinika za onkološku hirurgiju, Beograd, Srbija
  • Dusko Dundjerovic Institut za patologiju „Dr Đorđe Joannović“, Medicinski fakultet Univerziteta u Beogradu
  • Dejan Opric Institut za patologiju „Dr Đorđe Joannović“, Medicinski fakultet Univerziteta u Beogradu
  • Svetislav Tatic Institut za patologiju „Dr Đorđe Joannović“, Medicinski fakultet Univerziteta u Beogradu
  • Milica Labudovic Borovic Institut za histologiju i embriologiju „Prof. dr Aleksandar Đ. Kostić“, Medicinski fakultet Univerziteta u Beogradu
  • Svetlana Ristic Institut za onkologiju i radiologiju Srbije
  • Marko Buta Institut za onkologiju i radiologiju Srbije, klinika za onkološku hirurgiju, Beograd, Srbija
DOI: https://doi.org/10.5937/mckg58-50172
Keywords: breast cancer, neoadjuvant therapy, ER, PR, Ki-67

Abstract


Aim. The aim of this study is to evaluate the relationship between the immunohistochemical score of cell proliferation index Ki-67 and steroid receptor in patients with a pathohistological diagnosis of breast cancer. The impact of neoadjuvant therapy on biological markers in breast cancer remains controversial.

Methods. All patients with invasive breast cancer, as the primary and only malignancy, who underwent surgical and neoadjuvant therapy at the Institute of Oncology and Radiology of the Republic of Serbia (IORS) between 2017 and 2019 were included in the retrospective study. The expression level of Ki-67 and steroid receptors was detected by immunohistochemical analysis. Data were collected in an Excel database and analysed in the statistical softwer SPSS program version 25. For statistical data processing Chi-squared test, Kruskal-Wallis test and Mann-Whitney U test were used. For all statistical analysis, a p <0,05 was considered statistically significant and a p≤0.001 was considered highly statistically significant.

Results. The study included 190 patients with invasive breast cancer. The mean age of all patients at diagnosis was 57,2 ± 11,8 years. Among the patients, 64.2% are postmenopausal, 33.7% perimenopausal and 2.1% menopausal. There is a significant inverse correlation between the value of Ki-67 and the expression of steroid receptors.

Conclusion. The results demonstrated that the patients with higher values of the cell proliferative index Ki-67 are associated with lower values of estrogen receptors (ER) and progesterone receptors (PR). Different age categories are not correlated with Ki-67 expression.

References

1. Resende U, Cabello C, Ramalho SOB, Zeferino LC. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response. BMC Cancer. 2019 Dec 17;19(1):601.
2. Ragab HM, Samy N, Afify M, El Maksoud NA, Shaaban HM. Assessment of Ki-67 as a potential biomarker in patients with breast cancer. Journal of Genetic Engineering and Biotechnology. 2018 Dec;16(2):479–84.
3. Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Ulas A, et al. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. J BUON. 2015;20(1):45–9.
4. Rey-Vargas L, Mejía-Henao JC, Sanabria-Salas MC, Serrano-Gomez SJ. Effect of neoadjuvant therapy on breast cancer biomarker profile. BMC Cancer. 2020 Dec 18;20(1):675.
5. Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol. 2018 Jul 18;25(7):1783–5.
6. Madani SH, Payandeh M, Sadeghi M, Motamed H, Sadeghi E. The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients. Indian Journal of Medical and Paediatric Oncology. 2016 Apr 12;37(02):95–9.
7. Moisand A, Madéry M, Boyer T, Domblides C, Blaye C, Larmonier N. Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity. Int J Mol Sci. 2023 Oct 10;24(20):15048.
8. Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020 Jan 14;10(1):225.
9. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15;31(1):13–20.
10. Reis-Filho JS, Davidson NE. Ki67 Assessment in Breast Cancer: Are We There Yet? JNCI: Journal of the National Cancer Institute. 2021 Jul 1;113(7):797–8.
11. Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, et al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer. JAMA Oncol. 2018 Apr 1;4(4):545.
12. von Minckwitz G, Schmitt WD, Loibl S, Müller BM, Blohmer JU, Sinn B V., et al. Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer. Clinical Cancer Research. 2013 Aug 15;19(16):4521–31.
13. Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G, et al. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. Diagn Pathol. 2017 Dec 21;12(1):20.
14. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. JNCI Journal of the National Cancer Institute. 2011 Nov 16;103(22):1656–64.
15. Medley ML. Life Satisfaction across Four Stages of Adult Life. The International Journal of Aging and Human Development. 1980 Oct 1;11(3):193–209.
16. Kamranzadeh H, Ardekani R, Kasaeian A, Sadighi S, Maghsudi S, Jahanzad I, et al. Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study. Journal of Research in Medical Sciences. 2019;24(1):30.
17. NISHIMURA R, OSAKO T, NISHIYAMA Y, TASHIMA R, NAKANO M, FUJISUE M, et al. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol. 2014 Nov;2(6):1062–8.
18. Nahed AS, Shaimaa MY. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496.
19. Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, et al. Ki67 Index in Breast Cancer: Correlation with Other Prognostic Markers and Potential in Pakistani Patients. Asian Pacific Journal of Cancer Prevention. 2013 Jul 30;14(7):4353–8.
20. Kanyilmaz G, Benli Yavuz B, Aktan M, Karaagac M, Uyar M, Findik S. Prognostic Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic Factors. Eur J Breast Health. 2019 Oct 1;15(4):256–61.
Published
2024/06/30
Issue
Vol. 58 No. 1 (2024): MEDICINSKI ČASOPIS
Section
Original Scientific Paper